(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.47%) $79.63
(0.39%) $2.31
(0.56%) $2 353.30
(0.76%) $28.58
(0.23%) $993.10
(-0.31%) $0.927
(-0.45%) $10.84
(-0.25%) $0.798
(0.84%) $92.51
@ $82.43
Išleistas: 9 geg. 2024 @ 22:00
Grąža: 0.36%
Ankstesnis signalas: geg. 9 - 18:19
Ankstesnis signalas:
Grąža: 0.40 %
Live Chart Being Loaded With Signals
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally...
Stats | |
---|---|
Šios dienos apimtis | 1.91M |
Vidutinė apimtis | 3.60M |
Rinkos kapitalizacija | 37.76B |
EPS | $0 ( 2024-04-30 ) |
Kita pelno data | ( $0.970 ) 2024-07-23 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 24.05 |
ATR14 | $1.450 (1.75%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-01 | Jimenez Frank R | Buy | 1 315 | Common Stock, par value $0.01 per share |
2024-04-01 | Rott Roland | Sell | 837 | Common Stock, par value $0.01 per share |
2024-03-15 | General Electric Co | Sell | 14 000 000 | Common stock, par value $0.01 per share |
2024-03-01 | Westrick Thomas J. | Sell | 1 195 | Common Stock, par value $0.01 per share |
2024-03-01 | Westrick Thomas J. | Sell | 1 285 | Common Stock, par value $0.01 per share |
INSIDER POWER |
---|
-97.67 |
Last 99 transactions |
Buy: 735 929 | Sell: 57 991 119 |
Tūris Koreliacija
GE HealthCare Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
GE HealthCare Koreliacija - Valiuta/Žaliavos
GE HealthCare Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $19.55B |
Bruto pelnas: | $7.92B (40.52 %) |
EPS: | $3.04 |
FY | 2023 |
Pajamos: | $19.55B |
Bruto pelnas: | $7.92B (40.52 %) |
EPS: | $3.04 |
FY | 2022 |
Pajamos: | $18.34B |
Bruto pelnas: | $7.18B (39.14 %) |
EPS: | $4.22 |
FY | 2021 |
Pajamos: | $17.59B |
Bruto pelnas: | $7.17B (40.80 %) |
EPS: | $4.94 |
Financial Reports:
No articles found.
GE HealthCare
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, Hong Kong, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, image-guided therapy, and X-ray systems, as well as women's health products. The Ultrasound segment provides screening, diagnosis, treatment, and monitoring of certain diseases through radiology and primary care, women's health, cardiovascular, and point of care and handheld ultrasound solutions, as well as surgical visualization and guidance products. The Patient Care Solutions segment involved in the provision of medical devices, consumable products, services, and digital solutions through patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal infant care products. The Pharmaceutical Diagnostics supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, positron emission tomography, and ultrasound to the radiology and nuclear medicine industry. The segment also provides contrast media pharmaceuticals, administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents, or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes that are injected into a patient prior to a diagnostic imaging scan. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.